NeoPharm Crecimiento futuro
Future controles de criterios 2/6
Se prevé un crecimiento anual de los beneficios y los ingresos de NeoPharm de 18.1% y 15% por año respectivamente. Se prevé que el BPA crezca en un 16.5% al año. Se espera que la rentabilidad financiera sea de 15.6% en 3 años.
Información clave
18.1%
Tasa de crecimiento de los beneficios
16.5%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Personal Products | 10.4% |
| Tasa de crecimiento de los ingresos | 15.0% |
| Rentabilidad financiera futura | 15.6% |
| Cobertura de analistas | Low |
| Última actualización | 15 Oct 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
We Think That There Are Some Issues For NeoPharm (KOSDAQ:092730) Beyond Its Promising Earnings
Nov 20
The Returns On Capital At NeoPharm (KOSDAQ:092730) Don't Inspire Confidence
Nov 13NeoPharm CO., LTD.'s (KOSDAQ:092730) Earnings Are Not Doing Enough For Some Investors
Sep 13NeoPharm (KOSDAQ:092730) Will Want To Turn Around Its Return Trends
Aug 07NeoPharm CO., LTD. (KOSDAQ:092730) Stock Rockets 33% As Investors Are Less Pessimistic Than Expected
Jun 13Benign Growth For NeoPharm CO., LTD. (KOSDAQ:092730) Underpins Its Share Price
Apr 24NeoPharm's (KOSDAQ:092730) Earnings Are Weaker Than They Seem
Mar 25Does NeoPharm (KOSDAQ:092730) Have A Healthy Balance Sheet?
Mar 28What Is NeoPharm CO., LTD.'s (KOSDAQ:092730) Share Price Doing?
Mar 15How Much Did NeoPharm's(KOSDAQ:092730) Shareholders Earn From Share Price Movements Over The Last Three Years?
Mar 02We're Watching These Trends At NeoPharm (KOSDAQ:092730)
Feb 18We're Not So Sure You Should Rely on NeoPharm's (KOSDAQ:092730) Statutory Earnings
Feb 08
NeoPharm CO., LTD. (KOSDAQ:092730) Has Got What It Takes To Be An Attractive Dividend Stock
Jan 26An Intrinsic Calculation For NeoPharm CO., LTD. (KOSDAQ:092730) Suggests It's 31% Undervalued
Jan 15Will Weakness in NeoPharm CO., LTD.'s (KOSDAQ:092730) Stock Prove Temporary Given Strong Fundamentals?
Jan 04NeoPharm CO., LTD. (KOSDAQ:092730) Looks Like A Good Stock, And It's Going Ex-Dividend Soon
Dec 24What Is NeoPharm CO., LTD.'s (KOSDAQ:092730) Share Price Doing?
Dec 15Does NeoPharm (KOSDAQ:092730) Have A Healthy Balance Sheet?
Dec 04Would Shareholders Who Purchased NeoPharm's (KOSDAQ:092730) Stock Year Be Happy With The Share price Today?
Nov 23Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2026 | 157,300 | 33,750 | 35,700 | 35,700 | 2 |
| 12/31/2025 | 140,350 | 29,400 | 29,700 | 29,700 | 2 |
| 12/31/2024 | 120,200 | 24,700 | 23,000 | 23,000 | 1 |
| 9/30/2024 | 112,200 | 22,334 | -6,382 | 16,167 | N/A |
| 6/30/2024 | 107,858 | 22,929 | -3,941 | 17,678 | N/A |
| 3/31/2024 | 101,735 | 22,516 | -1,808 | 20,105 | N/A |
| 12/31/2023 | 97,105 | 23,213 | 2,435 | 23,263 | N/A |
| 9/30/2023 | 92,271 | 20,733 | 22,967 | 24,024 | N/A |
| 6/30/2023 | 89,292 | 19,781 | 20,199 | 21,423 | N/A |
| 3/31/2023 | 86,272 | 18,912 | 18,966 | 19,685 | N/A |
| 12/31/2022 | 85,033 | 17,027 | 17,354 | 18,161 | N/A |
| 9/30/2022 | 86,805 | 18,245 | 17,373 | 18,071 | N/A |
| 6/30/2022 | 87,424 | 17,370 | 17,809 | 18,258 | N/A |
| 3/31/2022 | 87,321 | 16,905 | 18,775 | 19,267 | N/A |
| 12/31/2021 | 87,931 | 17,713 | 21,203 | 21,681 | N/A |
| 9/30/2021 | 86,802 | 18,207 | 20,320 | 20,881 | N/A |
| 6/30/2021 | 85,275 | 18,059 | 21,190 | 21,766 | N/A |
| 3/31/2021 | 85,287 | 18,474 | 18,837 | 19,464 | N/A |
| 12/31/2020 | 81,625 | 18,131 | 16,343 | 17,074 | N/A |
| 9/30/2020 | 81,413 | 18,734 | 11,309 | 17,364 | N/A |
| 6/30/2020 | 82,618 | 19,935 | 12,028 | 18,544 | N/A |
| 3/31/2020 | 82,680 | 19,901 | 16,909 | 24,255 | N/A |
| 12/31/2019 | 83,240 | 19,245 | 12,030 | 19,224 | N/A |
| 9/30/2019 | 79,611 | 18,002 | 15,245 | 17,190 | N/A |
| 6/30/2019 | 74,863 | 16,675 | 13,488 | 15,234 | N/A |
| 3/31/2019 | 69,500 | 15,795 | 10,168 | 12,149 | N/A |
| 12/31/2018 | 66,275 | 15,370 | 14,096 | 16,179 | N/A |
| 9/30/2018 | 63,143 | 13,682 | 11,351 | 13,893 | N/A |
| 6/30/2018 | 60,236 | 13,105 | N/A | 14,629 | N/A |
| 3/31/2018 | 57,175 | 12,514 | N/A | 12,814 | N/A |
| 12/31/2017 | 53,634 | 11,559 | N/A | 10,646 | N/A |
| 9/30/2017 | 49,765 | 9,814 | N/A | 10,212 | N/A |
| 6/30/2017 | 46,739 | 9,365 | N/A | 9,866 | N/A |
| 3/31/2017 | 43,164 | 8,096 | N/A | 9,548 | N/A |
| 12/31/2016 | 42,369 | 7,742 | N/A | 9,157 | N/A |
| 9/30/2016 | 43,097 | 5,955 | N/A | 8,664 | N/A |
| 6/30/2016 | 41,999 | 5,419 | N/A | 6,471 | N/A |
| 12/31/2015 | 35,965 | 3,407 | N/A | 6,095 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (18.1% al año) de A092730 es superior a la tasa de ahorro (2.7%).
Beneficios vs. Mercado: Se prevé que los beneficios (18.1% al año) de A092730 crezcan menos que el mercado KR (28% al año).
Beneficios de alto crecimiento: Se prevé que los beneficios de A092730 crezcan, pero no significativamente.
Ingresos vs. Mercado: Se prevé que los ingresos (15% al año) de A092730 crezcan más rápidamente que los del mercado KR (9.4% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 15% al año) de A092730 crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de A092730 sea baja dentro de 3 años (15.6%).